Psychiatry organization does not endorse psychedelic treatment
A. Knopf
Alcoholism & Drug Abuse Weekly August 5, 2022 DOI: 10.1002/adaw.33520 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Position statement Peer reviewed |
|---|---|
| Key points | The APA warns about risks of unapproved psychedelic agents while acknowledging growing interest in their therapeutic potential for serious mental health conditions. |
Abstract
Last month the American Psychiatric Association (APA) issued a position statement on psychedelics warning about the short‐ and long‐term risks of these unapproved drugs. Sanctioned by the APA board of trustees, the “Position Statement on the Use of Psychedelic and Empathogenic Agents for Mental Health Conditions” notes that preliminary research involving psychedelics for the treatment of serious conditions, such as treatment‐resistant depression and post‐traumatic stress disorder, have motivated growing interest in the therapeutic potential of these agents.
Citations in the library
Cited by 3
- Perceptions and attitudes towards psychedelic-assisted psychotherapy among health professionals, patients, and the public: A systematic review Journal of Psychedelic Studies February 5, 2024
- Attitudes of European psychiatrists on psychedelics: a qualitative study. Frontiers in Psychiatry 2024
- Critical review of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: Unanswered questions and future directions Journal of Psychedelic Studies July 18, 2024